Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 23, 2023

Intermediate-Term Outcomes of Permissive Cardiotoxicity in Patients With Breast Cancer Receiving Trastuzumab

The Oncologist


Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab
Oncologist 2023 Apr 24;[EPub Ahead of Print], S Zhou, F Cirne, J Chow, A Zereshkian, L Bordeleau, S Dhesy-Thind, PM Ellis, SD Mukherjee, N Aghel, DP Leong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading